Pharmacovigilance study of amphotericin B for mucormycosis in post-COVID and non-COVID patients at a tertiary care hospital in Eastern India
CONCLUSION: AmphoB deoxycholate use in mucormycosis patients was associated with a high incidence of electrolyte abnormalities and infusion-related reactions. All ADRs subsided with medical management and none were fatal. The safety data generated from this study may be useful in resource-limited settings where the far more expensive liposomal formulation is not being used.
Source: Indian Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Suparna Chatterjee Manjari Bhattacharjee Avijit Hazra Pradip Mukhopadhyay Biman Kanti Ray Sayan Chatterjee Souvik Dubey Source Type: research
More News: Abelcet | Anemia | COVID-19 | Diabetes | Drugs & Pharmacology | Endocrinology | Fungal Infections | India Health | International Medicine & Public Health | Magnesium | Potassium | Study | WHO